bioMérieux Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Pierre Boulud

Chief Executive Officer (CEO)

€2.5m

Compensación total

Porcentaje del salario del CEO	25.7%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	12yrs

Actualizaciones recientes de la dirección

Recent updates

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Mar 15

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Jan 27

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

Jan 06

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 16

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Oct 23

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

Oct 05

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Sep 15

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Sep 07

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Jun 30

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Jun 09

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Mar 31

The Return Trends At bioMérieux (EPA:BIM) Look Promising

Feb 23

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jan 27

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

Dec 16

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Oct 18

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Sep 14

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Aug 11

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Jul 23

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jul 05

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

May 26

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

May 11

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

Apr 23

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

Apr 09

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Mar 25

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Mar 13

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Feb 08

Why We Like The Returns At bioMérieux (EPA:BIM)

Dec 21

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 07

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Nov 07

Is bioMérieux (EPA:BIM) A Risky Investment?

Oct 07

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Sep 22

Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

Sep 07

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Aug 06

There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

Jun 15

A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

May 31

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Apr 30

bioMérieux (EPA:BIM) Could Easily Take On More Debt

Mar 28

The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested

Mar 13

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Feb 25

If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns

Feb 09

If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late

Jan 20

Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?

Dec 30

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Dec 17

Has bioMérieux (EPA:BIM) Got What It Takes To Become A Multi-Bagger?

Dec 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pierre Boulud en comparación con los beneficios de bioMérieux?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€2m	€631k	€358m
Sep 30 2023	n/a	n/a	€372m
Jun 30 2023	n/a	n/a	€386m
Mar 31 2023	n/a	n/a	€419m
Dec 31 2022	€2m	€510k	€452m
Sep 30 2022	n/a	n/a	€502m
Jun 30 2022	n/a	n/a	€552m
Mar 31 2022	n/a	n/a	€577m
Dec 31 2021	€2m	€510k	€601m
Sep 30 2021	n/a	n/a	€555m
Jun 30 2021	n/a	n/a	€509m
Mar 31 2021	n/a	n/a	€457m
Dec 31 2020	€1m	€497k	€404m

Compensación vs. Mercado: La compensación total de Pierre($USD2.63M) está por debajo de la media de empresas de tamaño similar en el mercado French ($USD4.76M).

Compensación vs. Ingresos: La compensación de Pierre ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Pierre Boulud (52 yo)

less than a year

Permanencia

€2,452,864

Compensación

Mr. Pierre Boulud is Chief Executive Officer of bioMérieux S.A. from July 01, 2023. He served as Chief Operating Officer of Clinical Operations at BioMérieux S.A. until 2023 and served as its Chief Operati...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pierre Boulud	Chief Executive Officer	less than a year	€2.45m	sin datos
Guillaume Bouhours	Executive VP of Purchasing and Information Systems & CFO	6.2yrs	sin datos	sin datos
Sylvain Morgeau	Investor Relations	no data	sin datos	sin datos
Audrey Dauvet	Executive Vice President of Legal	1.3yrs	sin datos	sin datos
Valerie Leylde	Executive Vice President of Human Resources	5.3yrs	sin datos	sin datos
Pierre Charbonnier	Executive Vice President of Global Quality	6.2yrs	sin datos	sin datos
Yasha Mitrotti	Executive Vice President of Industrial Applications	6.2yrs	sin datos	sin datos
Frederic Beseme	Head of CSR	4.3yrs	€21.99k	0% € 0
Jennifer Zinn	Executive Vice President of Clinical Operations	less than a year	sin datos	sin datos
Charles Cooper	Executive VP & Chief Medical Officer	less than a year	sin datos	sin datos
Celine Roger-Dalbert	Executive Vice President of Research & Development	less than a year	sin datos	sin datos
Franck Admant	Director of Investor Relations	no data	sin datos	sin datos

2.8yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BIM se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Alain Merieux	Founding Chairman	6.8yrs	sin datos	sin datos
Jean-Luc Belingard	Non-Independent Director	17.7yrs	€52.00k	0.051% € 6.0m
Philippe Archinard	Non-Independent Director	13.9yrs	€61.00k	0.000030% € 3.5k
Alexandre Merieux	Chairman	20.1yrs	€1.92m	0.000050% € 5.9k
Harold Y. Boel	Independent Director	12yrs	€56.00k	0.00013% € 15.3k
Marie-Helene Habert-Dassault	Independent Director	12yrs	€44.00k	0.000050% € 5.9k
Fanny Letier	Independent Director	7yrs	€61.17k	0.000030% € 3.5k
Marie-Paule Kieny	Independent Director	6.8yrs	€35.00k	0.00015% € 17.6k
Sylvain Orenga	Employee Representative Director	2yrs	€52.00k	sin datos

12.0yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de BIM son experimentados ( 11.9 años antigüedad media).

bioMérieux Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

bioMérieux S.A., Annual General Meeting, May 23, 2024

Insufficient new directors

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A., Annual General Meeting, May 20, 2021

Recent updates

Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

Now 21% undervalued

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

New minor risk - Earnings quality

Dividend of €0.85 announced

bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

bioMérieux S.A., Annual General Meeting, May 23, 2024

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Upcoming dividend of €0.85 per share at 0.9% yield

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Third quarter 2022 earnings released: EPS: €0.95 (vs €1.37 in 3Q 2021)

The Return Trends At bioMérieux (EPA:BIM) Look Promising

bioMérieux Introduces GENE-UP ENVIROPRO

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

bioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE™

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: €1.93 (vs €2.34 in 1H 2021)

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Now 20% undervalued

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Now 22% undervalued

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Upcoming dividend of €0.85 per share

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

Insufficient new directors

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares in Specific Diagnostics, LLC for €360 million.

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire Specific Diagnostics, LLC.

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Price target decreased to €118

Full year 2021 earnings: EPS and revenues exceed analyst expectations

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Why We Like The Returns At bioMérieux (EPA:BIM)

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Price target increased to €124

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Is bioMérieux (EPA:BIM) A Risky Investment?

bioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection of STEC and Salmonella in Cannabis Flower for the GENE-UP® PRO STEC/ Salmonella Assay

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

First half 2021 earnings released: EPS €2.34 (vs €1.46 in 1H 2020)

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

Upcoming dividend of €0.62 per share

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

bioMérieux (EPA:BIM) Could Easily Take On More Debt

The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested